Eledon Pharmaceuticals reported its third quarter 2025 operating and financial results and reviewed recent business highlights.
Phase 2 BESTOW trial data demonstrated favorable safety and tolerability profile of tegoprubart, reducing toxicities associated with tacrolimus.
Strengthened balance sheet with $57.5 million financing to advance transplantation programs.
Phase 2 BESTOW Trial Results
Tegoprubart demonstrated excellent efficacy and safety, avoiding long-term toxicities of current standard-of-care immunosuppressive therapies.
Financial Highlights
Completed underwritten public offering resulting in $57.5 million gross proceeds, enhancing program advancement in transplantation.
Upcoming Milestones
Plans to enroll final patients in islet cell transplantation study, receive FDA guidance on Phase 3 trial design, and report long-term data in 2026.
- Tegoprubart showed promising results in preventing organ rejection and improving kidney function.
- Proceeds from financing provide resources to drive advancements in kidney transplantation, islet cell transplantation, and xenotransplantation.
Eledon Pharmaceuticals is on track for significant developments in transplantation therapies with promising trial results and strengthened financial position.